Among 2,714 U.S. cancer survivors aged 65+ drawn from ten NHANES cycles (1999–2018), statin use was independently associated with a 20% reduction in all-cause mortality (HR: 0.797, 95% CI: 0.705–0.901) in those with coronary heart disease (CHD), alongside meaningful reductions in cardiac mortality (HR: 0.765) and cancer-related mortality (HR: 0.774). In cancer survivors without CHD, statins were still linked to lower all-cause mortality (HR: 0.782) but showed no significant association with cardiac or cancer-specific deaths. Statin prevalence tripled over the study period, from 20% to 56%.
The cardiac mortality benefit among CHD patients is well-established and unsurprising — this replicates decades of trial evidence. What gives this analysis particular interest is the cancer-specific mortality signal. Statins have pleiotropic anti-inflammatory and anti-proliferative properties, and observational data suggesting cancer survival benefits has been accumulating, though causality remains unproven. The finding that the cancer mortality benefit appears only in CHD-positive survivors is biologically puzzling and may reflect confounding: CHD patients on statins may receive more intensive cardiovascular monitoring, improving overall care quality.
Critical limitations: this is a retrospective observational study with statin exposure measured at a single interview via 30-day recall — not a randomized trial. Adherence, statin type, dose, and duration are unmeasured. Healthy-user bias almost certainly inflates the benefit estimates. The authors rightly label these findings hypothesis-generating. For clinicians, the data reinforce statin use in older cancer survivors with CHD but cannot justify expanding prescribing purely for cancer mortality reduction.
